Crossject signed a partenering agreement for its ZENEO® Methotrexate product
Crossject signed a commercial partnership with Sayre Therapeutics, a company specialized in innovative treatments and medical devices commercialization in South Asia. They both agreed to provide Sayre Therapeutics with exclusive distribution and marketing rights in India, Bangladesh, Sri Lanka and Nepal. In return, Crossject will receive a share from 20% to 40% of the revenues generated from the product and Sayre has committed to minimum levels of volumes and marketing investment. The marketing authorization filing for this innovative product, aimed at treating rheumatoid arthritis, is anticipated early 2017 in the region.